Rezultaty - Alexander E. Perl

Redukuj rezultaty
  1. 1
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML od Alexander E. Perl

    Wydane 2017
    Dokumenty pełnotekstowe
    Revisão
    Dodaj do listy ulubionych książek
    Zapisane w:
  2. 2
    Availability of FLT3 inhibitors: how do we use them?

    Availability of FLT3 inhibitors: how do we use them? od Alexander E. Perl

    Wydane 2019
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Revisão
    Dodaj do listy ulubionych książek
    Zapisane w:
  3. 3
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML od Alexander E. Perl

    Wydane 2017
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Revisão
    Dodaj do listy ulubionych książek
    Zapisane w:
  4. 4
    Gilteritinib: potent targeting of FLT3 mutations in AML

    Gilteritinib: potent targeting of FLT3 mutations in AML od Mark J. Levis, Alexander E. Perl

    Wydane 2020
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Revisão
    Dodaj do listy ulubionych książek
    Zapisane w:
  5. 5
    Advances in patient care through increasingly individualized therapy

    Advances in patient care through increasingly individualized therapy od Courtney D. DiNardo, Alexander E. Perl

    Wydane 2019
    Dokumenty pełnotekstowe
    Revisão
    Dodaj do listy ulubionych książek
    Zapisane w:
  6. 6
    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemothera... od Alexander E. Perl, Margaret Kasner, Doris Shank, Selina M. Luger, Martin Carroll

    Wydane 2011
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  7. 7
    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia

    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia od Pamela J. Sung, Mayumi Sugita, Holly K. Koblish, Alexander E. Perl, Martin Carroll

    Wydane 2019
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  8. 8
    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib od Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci

    Wydane 2022
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  9. 9
    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations od Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith

    Wydane 2020
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  10. 10
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study od Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    Wydane 2019
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  11. 11
    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome od Ivana Gojo, Alexander E. Perl, Selina M. Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville

    Wydane 2013
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  12. 12
    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia od Christine M. McMahon, Jonathan Canaani, Bryan Rea, Rachel L. Sargent, Julianne Qualtieri, Christopher D. Watt, Jennifer J.D. Morrissette, Martin Carroll, Alexander E. Perl

    Wydane 2019
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  13. 13
    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia

    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia od Hagop M. Kantarjian, Nicholas J. Short, Courtney D. DiNardo, Eytan M. Stein, Naval Daver, Alexander E. Perl, Eunice S. Wang, Andrew H. Wei, Martin S. Tallman

    Wydane 2021
    Dokumenty pełnotekstowe
    Revisão
    Dodaj do listy ulubionych książek
    Zapisane w:
  14. 14
    A robust xenotransplantation model for acute myeloid leukemia

    A robust xenotransplantation model for acute myeloid leukemia od P V Sanchez, Robin Perry, Jean‐Emmanuel Sarry, Alexander E. Perl, Kathleen M. Murphy, Cezary Swider, Adam Bagg, John Choi, Jaclyn A. Biegel, Gwenn Danet-Desnoyers, Martin Carroll

    Wydane 2009
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  15. 15
    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML od Jorge E. Cortés, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis

    Wydane 2018
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  16. 16
    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220

    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220 od Panpan Hou, Chao Wu, Yuchen Wang, Rui Qi, Dheeraj Bhavanasi, Zhixiang Zuo, Cédric Dos Santos, Shuliang Chen, Yu Chen, Hong Zheng, Hong Wang, Alexander E. Perl, Deyin Guo, Jian Huang

    Wydane 2017
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  17. 17
    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations od Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason E. Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

    Wydane 2018
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  18. 18
    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL od Christian Hurtz, Gerald Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne W. Lehman, Yong Li, Asen Bagashev, Bryan Manning, Katherine D. Cummins, Janis K. Burkhardt, Alexander E. Perl, Martin Carroll, Sarah K. Tasian

    Wydane 2020
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  19. 19
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML od Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    Wydane 2012
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  20. 20
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) od Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    Wydane 2018
    Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:

Narzędzie wyszukiwania: